Q&A: FDA medical policy chief talks decentralized trial guidance, improving diversity

The FDA’s di­rec­tor of its Of­fice of Med­ical Pol­i­cy wants tri­al spon­sors to keep par­tic­i­pant ex­pe­ri­ences top-of-mind in their de­cen­tral­ized de­signs.

End­points News sat down …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.